Cure & Advancements/August 18, 2026/2 min read

New Research Platform Aims to Understand Why Type 1 Diabetes Affects People Differently

Greenstone Biosciences has received funding to create lab-grown pancreatic tissue from Type 1 diabetes patients. The research could help scientists better understand how insulin-producing cells respond to the disease and test new protective approaches.

News report — unverified, pending corroboration

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cure researchbeta cellsadvancements

Key takeaways

Researchers are building lab-grown pancreatic islet structures from cells donated by Type 1 diabetes patients to study how insulin-producing cells behave during disease
The project aims to create a resource that can help test potential therapies without relying solely on animal models or limited human tissue samples
Scientists hope this platform will reveal why Type 1 diabetes progresses differently in different people, even when they have similar autoimmune markers
The research is early-stage discovery work aimed at understanding disease biology, not an immediate treatment

Why This Research Matters

Type 1 diabetes develops when the immune system attacks insulin-producing beta cells in the pancreas. Yet the disease progresses differently in different people—even among those who have similar autoimmune markers. Scientists don't fully understand why some people lose insulin production quickly while others retain it longer.

Part of the challenge is that human pancreatic tissue is difficult to obtain, and animal models don't completely replicate how Type 1 diabetes develops in people. This gap has made it harder for researchers to test new ideas for protecting insulin-producing cells.

How the New Platform Works

Greenstone Biosciences, with support from Breakthrough T1D, plans to collect cells from a diverse group of Type 1 diabetes patients and reprogram them into induced pluripotent stem cells (iPSCs). These are cells that can develop into many cell types, including pancreatic beta cells.

The team will use these cells to grow three-dimensional pancreatic islet organoids—lab-grown structures that contain working insulin-producing beta cells. Researchers can then expose these organoids to inflammation, metabolic stress, and experimental therapies to see how the cells respond.

What Could Come Next

If successful, this platform could become a shared research resource for Type 1 diabetes scientists worldwide. It would allow many research groups to test protective therapies and study patient-to-patient differences in how cells respond to disease.

The work is focused on understanding disease biology—how beta cells behave in Type 1 diabetes and what might protect them. It represents early-stage discovery research aimed at generating insights that could inform future treatment approaches.

The Bigger Picture

Type 1 diabetes affects over 9.5 million people globally, a number expected to rise to 14.7 million by 2040. Better tools for understanding how the disease develops in individual patients could help researchers design more targeted approaches to preserving or restoring insulin production.

Evidence label

Origin: finance.yahoo.com (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.